CellAge targeting senescent cells using sythetic biology! Check out their new campaign video on Lifespan.io
Check out CellAge and their approach to removing senescent cells that accumulate with age and damage tissue regeneration.
https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/
Senolytics moving into human clinical trials in the next 18 months! One of the greatest pieces of biotech news of 2016.
The Silicon Valley drugmaker is part of a wave of new companies chasing after the fountain of youth.
By Caroline Chen Bloomberg
Continue reading “Anti-aging startup backed by Fidelity, Bezos raises $116 million” »
More progress with cancer and using a similar approach to senolytics, no surprise really as cancer and senescent cell share a lot of common ground and approach that work with one may well work with the other if they are aimed at inducing apoptosis.
Apoptosis, or programmed cell death, is a rapid and irreversible process to efficiently eliminate dysfunctional cells. A hallmark of cancer is the ability of malignant cells to evade apoptosis.
Dr Luminita Paraoan, from the University’s Department of Eye and Vision Science in the Institute of Ageing and Chronic Disease, has published new findings in the British Journal of Cancer that identify the requirement of a protein called p63 for the initiation of apoptosis in UM.
Continue reading “Protein that promotes ‘cell-suicide’ could revolutionise eye cancer treatment” »
The Goldilocks zone with telomere length is the key.
Ever since researchers connected the shortening of telomeres—the protective structures on the ends of chromosomes—to aging and disease, the race has been on to understand the factors that govern telomere length. Now, scientists at the Salk Institute have found that a balance of elongation and trimming in stem cells results in telomeres that are, as Goldilocks would say, not too short and not too long, but just right.
The finding, which appears in the December 5, 2016, issue of Nature Structural & Molecular Biology, deepens our understanding of stem cell biology and could help advance stem cell-based therapies, especially related to aging and regenerative medicine.
The fourth Lifespan.io campaign and CellAge are using synthetic biology to create an accurate aging biomarker for senescent cells and a new therapy for precision targeting of those problem cells. Senescent cells are one of the processes of aging and this could change the way we age.
Lifespan.io is proud to present our fourth rejuvenation biotechnology project!
Continue reading “CellAge: Targeting Senescent Cells With Synthetic Biology” »
In Brief
Though aging seems like one of the most natural things, an affair common to all living creatures, the process is actually poorly understood by scientists. A new study detailed in Nature aims to shed light on the phenomenon as a research team led by the Harvard T.H. Chan School of Public Health has uncovered a relationship between lifespan and RNA splicing, a core function of cells that allows a single gene to produce a variety of proteins.
The researchers already knew that mutations in RNA splicing could lead to disease, but they wanted to find out if the act of splicing itself had an impact on the aging process. To find out, they designed experimental setups using the roundworm Caenorhabditis elegans, which show visible signs of aging during their short three-week lifespan.
Continue reading “A New Aging Discovery Could Allow Humans to Extend Their Lifespan” »
Infertile women have been offered new hope after scientists found that a common cancer drug triggers the development of new eggs, an outcome which was previously thought to be impossible.
In a discovery hailed as “astonishing”, researchers at the University of Edinburgh proved it is possible to reverse the clock and coax the ovaries back into a pre-pubescent state where they begin to produce new eggs.
Women are born with all their eggs, which is why conceiving becomes harder with age, because the eggs grow old, become damaged and eventually run out entirely.
The full antiaging rejuvenation toolkit of the next few decades will consist of a range of different treatments, each targeting a different type of molecular damage in cells and tissues. Fightaging predicts the likely order of arrival of some of these therapies, based on what is presently going on in research, funding, and for-profit development.
1) Clearance of Senescent Cells
Everon Biosciences, Oisin Biotechnologies, SIWA Therapeutics, and UNITY Biotechnology are all forging ahead with various different approaches to the selective destruction of senescent cells. No doubt many groups within established Big Pharma entities are also taking a stab at this, more quietly, and with less press attention. UNITY Biotechnology has raised more than $100 million to date, demonstrating that there is broad enthusiasm for this approach to the treatment of aging and age-related disease.
Continue reading “Fight Aging predicts the sequence of arrival for meaningful antiaging therapies” »
Please support SENS Research on Amazon Smile this Christmas smile
Dont forget you can help SENS Research Foundation even during your Christmas shopping this year! Using Amazon Smile you can buy your gifts in the normal way but Amazon will donate 0.5% of the price of your eligible AmazonSmile purchases to us whenever you shop on AmazonSmile. bigsmile
#aging #sens
